{"status":"OK","data":{"id":2694107,"identifier":"DVN/LLRBBD","persistentUrl":"https://doi.org/10.7910/DVN/LLRBBD","protocol":"doi","authority":"10.7910","publisher":"Harvard Dataverse","publicationDate":"2015-07-15","storageIdentifier":"s3://dvn-cloud:10.7910/DVN/LLRBBD","latestVersion":{"id":75719,"storageIdentifier":"s3://dvn-cloud:10.7910/DVN/LLRBBD","versionNumber":1,"versionMinorNumber":0,"versionState":"RELEASED","productionDate":"Production Date","lastUpdateTime":"2015-07-15T12:31:47Z","releaseTime":"2015-07-15T12:31:47Z","createTime":"2015-07-15T12:27:30Z","license":"CC0","termsOfUse":"CC0 Waiver","metadataBlocks":{"citation":{"displayName":"Citation Metadata","fields":[{"typeName":"title","multiple":false,"typeClass":"primitive","value":"Replication Data for: Presentation to FDA 20150715"},{"typeName":"author","multiple":true,"typeClass":"compound","value":[{"authorName":{"typeName":"authorName","multiple":false,"typeClass":"primitive","value":"Carpenter, Daniel"},"authorAffiliation":{"typeName":"authorAffiliation","multiple":false,"typeClass":"primitive","value":"Harvard"}}]},{"typeName":"datasetContact","multiple":true,"typeClass":"compound","value":[{"datasetContactName":{"typeName":"datasetContactName","multiple":false,"typeClass":"primitive","value":"Carpenter, Daniel"},"datasetContactAffiliation":{"typeName":"datasetContactAffiliation","multiple":false,"typeClass":"primitive","value":"Harvard"},"datasetContactEmail":{"typeName":"datasetContactEmail","multiple":false,"typeClass":"primitive","value":"dcarpenter@gov.harvard.edu"}}]},{"typeName":"dsDescription","multiple":true,"typeClass":"compound","value":[{"dsDescriptionValue":{"typeName":"dsDescriptionValue","multiple":false,"typeClass":"primitive","value":"Data on new drugs and biologics reviewed and approved by the FDA's Center for Drug Evaluation and Research from 2011 to 2015. Used for Professor Carpenter's presentation to the U.S. Food and Drug Administration on July 15, 2015, on the Prescription Drug User Fee Act of 2017."}}]},{"typeName":"subject","multiple":true,"typeClass":"controlledVocabulary","value":["Medicine, Health and Life Sciences"]},{"typeName":"keyword","multiple":true,"typeClass":"compound","value":[{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"FDA"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"decision time"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"public management"}},{"keywordValue":{"typeName":"keywordValue","multiple":false,"typeClass":"primitive","value":"drug approval"}}]},{"typeName":"depositor","multiple":false,"typeClass":"primitive","value":"Carpenter, Daniel"},{"typeName":"dateOfDeposit","multiple":false,"typeClass":"primitive","value":"2015-07-15"}]}},"files":[{"label":"datapost-fdapresentation20150715.xls","restricted":false,"version":1,"datasetVersionId":75719,"dataFile":{"id":2694108,"persistentId":"doi:10.7910/DVN/LLRBBD/YMAT7T","pidURL":"https://doi.org/10.7910/DVN/LLRBBD/YMAT7T","filename":"datapost-fdapresentation20150715.xls","contentType":"application/vnd.ms-excel","filesize":26624,"storageIdentifier":"s3://dvn-cloud:14e91aef48b-26a476f5744a","rootDataFileId":-1,"md5":"89ad25f76fb57c02ceebf743667bb93f","checksum":{"type":"MD5","value":"89ad25f76fb57c02ceebf743667bb93f"}}}]}}}